Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes

[1]  B. Brüne,et al.  Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure , 2018, JAMA cardiology.

[2]  J. Perkins,et al.  TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome , 2017, Clinical lymphoma, myeloma & leukemia.

[3]  R. Geffers,et al.  Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation , 2017, Annals of Hematology.

[4]  S. Miyano,et al.  Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. , 2017, Blood.

[5]  D. Neuberg,et al.  Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.

[6]  P. Vyas,et al.  Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. , 2016, Blood advances.

[7]  M. Carroll,et al.  Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  R. Bellazzi,et al.  Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Maciejewski,et al.  Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes , 2016, Leukemia.

[10]  S. Nahas,et al.  Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes , 2016, Leukemia.

[11]  D. Grimwade,et al.  Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. , 2016, Blood.

[12]  S. Miyano,et al.  Impact of Somatic Mutations on Outcome in Patients with MDS after Stem-Cell Transplantation , 2015 .

[13]  J. Maciejewski,et al.  Prognostic Impact of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes: Adverse Impact of TET2 Mutations , 2015 .

[14]  Xia Li,et al.  Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 , 2015, Nature.

[15]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[16]  D. Neuberg,et al.  Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[18]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[19]  Torsten Haferlach,et al.  Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[21]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .

[22]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.